Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Operating Income (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Operating Income for 13 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 212.1% year-over-year to -$2.2 million, compared with a TTM value of -$7.2 million through Dec 2025, down 51.98%, and an annual FY2025 reading of -$7.2 million, down 51.98% over the prior year.
  • Operating Income was -$2.2 million for Q4 2025 at Abvc Biopharma, down from -$2.0 million in the prior quarter.
  • Across five years, Operating Income topped out at -$302316.0 in Q3 2024 and bottomed at -$6.4 million in Q4 2021.
  • Average Operating Income over 5 years is -$2.3 million, with a median of -$2.0 million recorded in 2021.
  • The sharpest move saw Operating Income surged 85.97% in 2024, then tumbled 549.77% in 2025.
  • Year by year, Operating Income stood at -$6.4 million in 2021, then skyrocketed by 51.41% to -$3.1 million in 2022, then skyrocketed by 83.66% to -$511835.0 in 2023, then tumbled by 37.65% to -$704564.0 in 2024, then crashed by 212.1% to -$2.2 million in 2025.
  • Business Quant data shows Operating Income for ABVC at -$2.2 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.3 million in Q2 2025.